Evidence map›Paper›PMID 42453943›Full record

Articlenpj women's health2026

Combination of oxidative phosphorylation and platelet-derived growth factor inhibitors for the treatment of ovarian cancers.

Kathleen M Burkhard, Taylor Repetto, Geeta Mehta

Abstract read
In one paragraph

Article in npj women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kathleen M Burkhard *Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI USA.ORCID 0009-0002-0141-5024
Taylor Repetto *Department of Materials Science and Engineering, University of Michigan, Ann Arbor, MI USA.ORCID 0009-0001-1001-1681
Geeta MehtaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI USA.ORCID 0000-0001-5967-6425

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

The combination therapy of FDA approved oxidative phosphorylation inhibitors (metformin and atovaquone) and platelet derived growth factor inhibitors (sunitinib and sorafenib) could target ovarian cancer stem-like cells (CSCs) and carcinoma associated mesenchymal stem cell enrichment of CSCs while reducing off-target effects. Results of a 48-hour drug exposure ovarian cancer-MSC tumoroid model showed additive effects with atovaquone combined with sunitinib or sorafenib being most effective.

Indexed as

CancerCell biologyDrug discoveryOncologyStem cells

Identifiers

PMID42453943
PMCPMC13364701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.